NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

手術用人工血管市場 - 預測(2021年∼2026年)

Vascular Graft Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023201
出版日期 內容資訊 英文 111 Pages
商品交期: 最快1-2個工作天內
價格
手術用人工血管市場 - 預測(2021年∼2026年) Vascular Graft Market - Forecasts from 2021 to 2026
出版日期: 2021年07月07日內容資訊: 英文 111 Pages
簡介

全球手術用人工血管的市場規模,預計從2019年的56億3700萬美元到2026年達到79億5500萬美元,在預期期間以5.04%的年複合成長率成長。

越來越多的心血管疾病、腎功能衰竭、靜脈疾病患者,全球老年人口不斷增加,公眾對預防保健的興趣日益增加,對穩固未來的重要性日益增加,醫療服務管理日益採用直接面向購物者的方法,成為在2021-2028年預測期間推動血管市場發展的關鍵因素。

本報告提供全球手術用人工血管市場調查,在市場概要和趨勢,企業間的競爭情形,各材料、各適應症、各地區的市場分析等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 假設

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 波特的五力分析
    • 供給企業的競爭力
    • 購買企業的競爭力
    • 新加入業者的威脅
    • 替代品的威脅
    • 功能的競爭企業間的競爭關係
  • 功能價值鏈分析

第5章 各材料:手術用人工血管市場分析

  • 簡介
  • 人工
  • 混合
  • 生物材料

第6章 各適應症:手術用人工血管市場分析

  • 簡介
  • 心血管疾病
  • 腎臟疾病
  • 動脈瘤
  • 其他

第7章 各終端用戶:手術用人工血管市場分析

  • 簡介
  • 醫院和診所
  • 門診病人手術中心

第8章 各地區:手術用人工血管市場分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 其他
  • 中東和非洲
    • 以色列
    • 沙烏地阿拉伯
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他

第9章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業和市場收益性
  • 合併,收購,協定,共同研究
  • 供應商競爭力 矩陣

第10章 企業簡介

  • Hancock Jaffe Laboratories, Inc.
  • Getinge Group
  • W. L. Gore & Associates
  • Vascular Flow Technologies
  • C. R. Bard, Inc.
  • Artegraft Inc.
  • Vascular Genesis
  • B. Braun Melsungen AG
  • LeMaitre Vascular, Inc.
  • Terumo Aortic
目錄
Product Code: KSI061611564

The global vascular graft market is expected to grow at a compound annual growth rate of 5.04% over the forecast period to reach a market size of US$7.955 billion in 2026 from US$5.637 billion in 2019. The vascular graft is a significant technique to carefully treat infected or harmed veins to re-establish the bloodstream by supplanting the veins. Supplanting solid veins ideal would guarantee an expanded future and this gives more authority over tolerant wellbeing. An increasing number of patients experiencing cardiovascular infections, renal disappointment, sick veins, attributable to expanding predominance of geriatric populace across the globe, expanding focal point of the public authority towards preventive medical care, rising significance of solid future, expanding appropriation of direct to shopper approach for the accessibility of medical services administrations are a portion of the major just as significant components which will liable to increase the development of the vascular graft market in the projected time span of 2021-2028. Then again, expanding the number of exploration exercises, developing utilization of separating accuracy and customized medications which will additionally contribute by creating enormous freedoms that will prompt the development of the vascular graft market in the forthcoming years.

Nonetheless, instability in the costs of grafts offered by various organizations alongside expanding issues of transport of tests will be prone to go about as market restrictions factor for the development of the Vascular graft in the previously mentioned projected time span. The absence of repayment strategies will turn into the greatest and chief test for the development of the market.

Growth Factors.

  • Growth of the cardiac aneurysms industry.

The growth of the cardiac aneurysms industry due to factors such as the high prevalence of high blood pressure and the advent of advanced tissue-engineered grafts for pediatric congenital heart surgeries is expected to further boost the growth of the vascular graft market as well. Besides, the advancement of novel prosthetic grafts with improved porosity and proficiency combined with developing acknowledgment for these grafts are projected to drive the item interest. Expanding geriatric populace and unfortunate way of life propensities, like liquor utilization and smoking, are expected to drive the interest for negligibly obtrusive grafting techniques. Expanding the number of treatment disappointments for CVDs, like the disappointment of organ transplantation, careful remaking, and ominous results because of mechanical gadgets, are relied upon to trigger interest for insignificantly obtrusive vascular inserts. Thus, increasing demand for minimally invasive implants is expected to drive the demand for vascular graft for cardiac aneurysms over the forecast period.

Restraints.

  • Possibility of vascular graft infection.

Vascular graft infection is a rare but potentially devastating complication. Even with improving clinical and careful procedures, this intricacy stays the most genuine occasion after a blood vessel prosthetic substitution. A cautious clinical test of a patient who got a vascular graft is significant because the doubt of graft disease is consistently present. Due to the maturing of the populace, treating more seasoned or immunologically discouraged patients is more normal, thus elective techniques to decrease the substantial effect of the mediation have been recommended. Among these, ultrasound debridement of the contaminated tissues, and of the graft, is a possibility for moderate treatment with great outcomes at follow-up. Thus, the fear of contracting an infection from a vascular graft as well as the availability of alternate solutions like ultrasound debridement is expected to hurt the vascular graft market during the forecast period.

Impact of COVID - 19.

Over the most recent couple of months, the quantity of patient visits to clinics has decreased essentially, regardless of crisis and OPD administrations being accessible in emergency clinics. Before beginning any interventional technique, specialists go through a progression of clinical tests to choose the best treatment for patients. Nonetheless, because of the lockdown in numerous nations, patient visits to medical clinics have decreased altogether. Therefore, the quantity of indicative tests has diminished. This has additionally diminished the deals of vascular grafts. Globally, a larger part of nations has deferred elective medical procedures to forestall the spread of COVID-19. Since 70-80% of vascular grafts, interventional strategies are elective, a significant number of these systems have been postponed. This is another factor contrarily affecting the development of the vascular grafts market. Additionally, shut assembling offices because of lockdowns disturbed stock chains, and diminished enlistments for clinical preliminaries are additionally expected to affect the development of the global vascular grafts market.

Competitive Insights.

The increasing demand for vascular grafts caused by the increasing prevalence of cardiac aneurysms and cardiovascular disease across the world has led to the entry of several new players like Stryker in the vascular graft market. The entry of these new players in a market where traditional pharma behemoths like C. R. Bard, Inc. and Artegraft Inc. already exist, is expected to lead to further innovation in the vascular grafts market. Moreover, in order to further increase their clientele as well as increase their market share in the upcoming years, many of these market players have taken various strategic actions like partnerships and development of novel solutions which primarily focus on providing comfort to the patient, which is expected to keep the market competitive and constantly evolving.

Market Segmentation:

  • By Source
  • Synthetic
  • Semi Synthetic
  • Natural
  • By Indication
  • Cardiovascular Diseases
  • Renal Diseases
  • Aneurysms
  • Others
  • By End-Users
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Israel
  • Saudi Arabia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Function
  • 4.4. Function Value Chain Analysis

5. Vascular Graft Market Analysis, By Source

  • 5.1. Introduction
  • 5.2. Synthetic
  • 5.3. Semi-Synthetic
  • 5.4. Natural

6. Vascular Graft Market Analysis, By Indication

  • 6.1. Introduction
  • 6.2. Cardiovascular Diseases
  • 6.3. Renal Diseases
  • 6.4. Aneurysms
  • 6.5. Others

7. Vascular Graft Market Analysis, By End-Users

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Ambulatory Surgical Centers

8. Vascular Graft Market Analysis, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. Germany
    • 8.4.3. Italy
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Israel
    • 8.5.2. Saudi Arabia
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. South Korea
    • 8.6.6. Taiwan
    • 8.6.7. Thailand
    • 8.6.8. Indonesia
    • 8.6.9. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles.

  • 10.1. Hancock Jaffe Laboratories, Inc.
  • 10.2. Getinge Group
  • 10.3. W. L. Gore & Associates
  • 10.4. Vascular Flow Technologies
  • 10.5. C. R. Bard, Inc.
  • 10.6. Artegraft Inc.
  • 10.7. Vascular Genesis
  • 10.8. B. Braun Melsungen AG
  • 10.9. LeMaitre Vascular, Inc.
  • 10.10. Terumo Aortic